Creating cleaner and safer nursing homes for elderly residents throughout the UK.

Older To From First Silver Trial In UK Nursing Home BenefitThe results of the first silver was released antimicrobial product testing in a nursing home environment in the British Journal of Nursing Community, that levels of potentially deadly bacteria are drastically reduced using products with silver antimicrobial treatment, creating cleaner and safer nursing homes for elderly residents throughout the UK.

Both Units The average difference in bacterial count was 94.8 %. Richard Hastings, BioCote Ltd microbiologist, commented: ‘This is yet another clear signal that BioCote treated products besides cleaning methods that contribute to low levels of bacteria on surfaces and used in other medical setting can be of particular significance nursing home nursing home sector, as they are now stringent stringent infection prevention and control strategies. Medicare Prescription Drug coverage offered to all Medicare beneficiaries in January 2006 with the implementation of the Medicare Prescription Drug Coverage or Medicare Part D. In January 2006, Medicare Prescription Drug coverage to certain beneficiaries, such as people with the necessarily limited necessary dialysis or transplantation due to severe kidney disease.

– The number of Medicare beneficiaries who had one or more payments by Medicare for one or more prescription drugs increased from about 21 % to almost 69 %..The co-primary endpoints of the trial will reductions in average frequency of moderate to heavy flushing, and the mean severity of hot flushes, for four and 12 weeks of stably treat are measuring. As in the prior the Breeze 1 study , the the treatment study period are to be 24 weeks to compare the opinion which FDA, plans to should be well show statistically significant persistence efficacy at week 24 to tackle. The study will a responder analysis, to assess the clinical significance a reduction of the frequency hot flashes in active arm opposite the placebo arm..

Initiate FDA guidance and plans to continue Phase 3 clinical trial evaluating non-hormonal therapy for menopausal hot flushes.